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Background: We have previously shown that EphrinA1/EphA expression profile changes in response to myocardial
infarction (MI), exogenous EphrinA1-Fc administration following MI positively influences wound healing, and that
deletion of the EphA2 Receptor (EphA2-R) exacerbates injury and remodeling. To determine whether or not
ephrinA1-Fc would be of therapeutic value in the hyperglycemic infarcted heart, it is critical to evaluate how
ephrinA1/EphA signaling changes in the hyperglycemic myocardium in response to MI.
Methods: Streptozotocin (STZ)-induced hyperglycemia in wild type (WT) and EphA2-receptor mutant (EphA2-R-M)
mice was initiated by an intraperitoneal injection of STZ (150 mg/kg) 10 days before surgery. MI was induced by
permanent ligation of the left anterior descending coronary artery and analyses were performed at 4 days post-MI.
ANOVAs with Student-Newman Keuls multiple comparison post-hoc analysis illustrated which groups were
significantly different, with significance of at least p < 0.05.
Results: Both WT and EphA2-R-M mice responded adversely to STZ, but only hyperglycemic EphA2-R-M mice had
lower ejection fraction (EF) and fractional shortening (FS). At 4 days post-MI, we observed greater post-MI mortality
in EphA2-R-M mice compared with WT and this was greater still in the EphA2-R-M hyperglycemic mice. Although
infarct size was greater in hyperglycemic WT mice vs normoglycemic mice, there was no difference between
hyperglycemic EphA2-R-M mice and normoglycemic EphA2-R-M mice. The hypertrophic response that normally
occurs in viable myocardium remote to the infarct was noticeably absent in epicardial cardiomyocytes and cardiac
dysfunction worsened in hyperglycemic EphA2-R-M hearts post-MI. The characteristic interstitial fibrotic response in
the compensating myocardium remote to the infarct also did not occur in hyperglycemic EphA2-R-M mouse hearts
to the same extent as that observed in the hyperglycemic WT mouse hearts. Differences in neutrophil and
pan-leukocyte infiltration and serum cytokines implicate EphA2-R in modulation of injury and the differences in
ephrinA1 and EphA6-R expression in governing this are discussed.
Conclusions: We conclude that EphA2-mutant mice are more prone to hyperglycemia-induced increased injury,
decreased survival, and worsened LV remodeling due to impaired wound healing.
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Diabetes affects nearly 6% of the US population and
about 30% of acute coronary syndrome patients hospita-
lized have diabetes [1]. In 2004, 68% of diabetes-related
deaths were associated with heart disease. Morbidity,
mortality, and re-infarction rates are 2-4 times higher
following MI in diabetic than in non-diabetic subjects,
with one-year mortality in this population as high as
50% [2]. Despite the evidence for improved outcomes
from cardiovascular disease in the general population
over the past three decades, these benefits have not been
paralleled in the diabetic population since the diabetic
heart is refractory to known cardioprotective approaches.
The heart, being a terminally differentiated organ, lacks
endogenous regenerative capacity and thus, developing
techniques to maximize myocardial salvage post MI
continues to be a health care priority.
The Eph receptors and their cognate ligands, the ephrins
are the largest family of receptor tyrosine kinases (RTKs)
and their signaling has been implicated in various cellular
processes during embryogenesis, tumorigenesis, vasculo-
genesis and in the regulation of inflammation and apop-
tosis [3–12]. Previous research has shown that exogenous
administration of EphrinA1-Fc following an ischemic event
reduces cardiac injury by reducing cardiomyocyte death
and inflammation, and promoting tissue regeneration
[13–15]. To investigate whether or not ephrinA1-Fc also
has potential therapeutic value in the hyperglycemic heart,
it is first necessary to compare and contrast ephrinA/EphA
expression in WT hyperglycemic and normoglycemic
myocardium versus hyperglycemic and normoglycemic
EphA-2-R-M myocardium following an MI. We hypo-
thesize that EphrinA1/EphA signaling is differentially and
unfavorably influenced by hyperglycemia in EphA2-R-M
mice and that injury, remodeling, and dysfunction are
further exacerbated by hyperglycemia.
Our results indicate that in mice lacking a functional
EphA2-R, hyperglycemia worsens remodeling and cardiac
function post-MI and this is due to an aggravated inflam-
matory response, poor infarct resolution, and inadequate
healing. This is at least in part due to insufficient pro-
duction of endogenous protective ephrinA1 in both
normoglycemic and hyperglycemic WT and EphA2-R-M
mice as well as increased EphA6 expression in EphA2-R-M
compared to WT mice. We conclude that exogenous
administration of EphrinA1 would be of therapeutic value
in the hyperglycemic heart and EphA2 is necessary for
appropriate signal transduction. Further studies to assess
this are in progress.
Methods
Ethical approval
All procedures were approved by the East Carolina
University Institutional Animal Care and Use Committeeand the investigation conforms to the Guide for the
Care and Use of Laboratory Animals published by the
US National Institutes of Health.
Animals
WT129SF2/J mice (stock #101045) (WT) and WT129S6-
Epha2tm1Jrui/J (stock #006028; a pan-knockout; EphA2-R-M)
mice aged 8-12 weeks were used in these experiments.
Male mice were housed in individually ventilated cages
and animal care was maintained by the Department of
Comparative Medicine at The Brody School of Medicine
at East Carolina University. Mice were exposed to 12 h/
12 h light/dark cycle conditions and received food and
water ad libitum.
Blood glucose
WTand EphA2-R-M mice were given an intraperitoneal
injection of 150 mg/kg of streptozotocin (STZ) or
0.1 mol/l of citrate buffer. Mice became diabetic (as evi-
dence by polyuria and polydipsia) at least 1 week prior
to surgery. Ten days after the STZ/citrate injection, but
prior to surgery, mice were fasted for 4 hours and blood
glucose levels were measured (OneTouch Ultra gluc-
ometer, Lifescan, CA, USA). Mice were considered hyper-
glycemic if blood glucose was greater than 200 mg/dl.
There were four groups of control mice and 4 groups of
infarcted mice (WT citrate, WT STZ, EphA2-R-M citrate,
and EphA2-R-M STZ) from which tissue was collected for
analysis 4 days post-MI.
Surgical procedure, cardiac function and tissue collection
Myocardial infarction was induced by permanently ligat-
ing the left coronary artery in anesthetized, mechanically
ventilated mice. Briefly, male WT and EphA2-R-M mice
(8-12 weeks) were anesthetized with an intraperitoneal
(IP) injection of 20 μl/g body weight Avertin (20 mg/ml), a
left thoracotomy performed, and the left anterior de-
scending coronary artery was permanently occluded
using an 8-0 suture. The rib cage, muscle, and skin were
then closed with a 6-0 suture. Uninjured sham controls
underwent the entire procedure including suture pass
under the coronary [13,16].
Echocardiography was performed on conscious mice
at 4 days post-MI. A VisualSonics Vevo 2100 diagnostic
ultrasound, using M-mode and 30 MHz probe, was used
to obtain LV dimensions in diastole and systole. End-
diastolic measurements of interventricular septal thickness
(IVSd), left ventricular posterior wall thickness (LVPWd),
and left ventricular internal diameter (LVIDd) were ob-
tained at the point of maximal LV diastolic dimension.
End-systolic dimensions (IVSs, LVPWs, and LVIDs) were
measured at the time of most anterior systolic excursion
of the LVPW associated with minimal chamber dimen-
sion. Average measurements were calculated using the
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beats. Ejection fraction (EF) was calculated from LV di-
mensions above using the following formula: (LVIDd3 –
LVIDs3)/LVIDd3 × 100%. FS was calculated using the
formula (LVIDs-LVIDs)/LVIDd × 100% [17].
At the time of sacrifice, mice were anesthetized with
an IP injection of 0.1 mL pentobarbital (390 mg/mL)
and a pneumothorax was performed. Hearts to be used
for histology and immunohistochemistry were arrested
in diastole using cold KCl (30 mM), excised, rinsed in
PBS, and immersed in zinc fixative. For RNA and protein
analyses, the right ventricle was dissected away from the
heart and discarded while the remaining left ventricle was
snap frozen in liquid nitrogen.
Histology, morphometry, and immunohistochemistry
Tissue was harvested and immersed in zinc fixative, then
processed and embedded in paraffin as per routine proce-
dures. For immunohistochemical staining and morpho-
metric measurements, whole hearts were transversely
sectioned into 4 slices of equal thickness, processed in
an automated tissue processor (TP1020, Leica, Nußloch,
Germany), and embedded in paraffin (MICROM EC350,
Richard-Allan Scientific, Kalamazoo, MI, USA) [18,19].
Blocks were then sectioned into 5um sections and
mounted on Superfrost Plus glass slides for histologic or
immunohistochemical staining.
Morphometric measurements of the left ventricle, in-
farct area, and chamber area were performed on tissue
sections 4 days post-MI (n = 7-12/group). Images of 4
hematoxylin and eosin (H&E)-stained sections of each
heart were taken at × 20 magnification using a DP70
digital camera. Myocyte cross-sectional area (MCSA) was
measured in 3-8 cardiomyocytes with centrally located nu-
clei in each of 6 images (600×) in the endocardium and
epicardium (n = 3-5/group) using Scion imaging software
(Scion Corporation, Frederick, MD, USA).
Slides stained with picrosirius red for fibrillar collagen
and fast green for contrast were used to quantify inters-
tial fibrosis [20]. Adobe Photoshop software was used to
count the red collagen fibril pixels which were expressed
as a percentage of the total number of pixels (total =
green + red - white) in five images at 400× taken in each
of 2 cross sections per heart remote to the infarct but in
the same plane.
Tissue sections were deparaffinized in xylene and
endogenous peroxidases quenched with 3% H2O2 in
methanol. As described elsewhere previously, slides were
rinsed in PBS and incubated with Ly6G (BD Biosciences,
#550291) to assess neutrophil infiltration, CD45 (BD
Biosciences; #550539) for macrophage density [13,19–22].
Isolectin B4 (Vector Labs;B-1205) or CD31 (BD Biosci-
ences, #553371) was used to measure capillary density
in uninjured control and infarcted hearts respectively[19]. Slides were incubated with appropriate biotinyl-
ated secondary antibodies and then with Avidin Biotin
Complex (Vector Labs PK-6100). The reaction product
was visualized with DAB (Vector, SK-4100), counter-
stained with methyl green, dehydrated in xylene, and
slides were coverslipped.
ELISA
A mouse cytokine proteome profiler array (R&D #ARY006)
was used to compare levels of 40 serum cytokines as
per manufacturer’s protocol. Forty microliters from
each of 5 different samples were combined for each
group. The samples were run in duplicate and data are
expressed as relative expression (pixel density = relative
units) with levels appropriately normalized to internal
reference spot controls.
qRT-PCR
Whole left ventricles from mice 4 days post-MI were ho-
mogenized using Trizol for RNA isolation. Purification
was performed using the Qiagen RNeasy kit. cDNA was
made for each sample using a high capacity cDNA kit.
Real-time PCR (qRT-PCR) performed using an Applied
Biosystems thermocycler. TaqMan primers were obtained
from Applied Biosciences (ephrinA1: Mm00438660_m1,
EphA1: Mm00445804_m1, EphA3: Mm00580743_m1,
EphA4: Mm00433056_m1, EphA5: Mm00433074_m1,
EphA6: Mm00433094_m1, EphA7: Mm00833876_m1,
GAPDH: Mm99999915_g1). All samples were run in
triplicate and a reaction mixture of 10 μl (100 ng RNA)
was amplified using recommended conditions from
Applied Biosciences. Gene expression was normalized
to expression of GAPDH. Fluorescence data were ana-
lyzed using the ΔΔ Ct method.
Western blotting
Whole left ventricles of uninjured sham control hearts
and hearts 4 days post-MI from each of the 8 groups of
mice were homogenized in a lysis buffer containing
50 mM Hepes, 10 mM EDTA, 100 mM NaF, 50 mM so-
dium pyrophosphate, 1% protease, and 1% phosphatase
inhibitors. The Bradford Assay was used to quantify the
amount of protein. Western blotting was performed on
a 4–12% gradient Bis-Tris gel (BioRad) in 1× Mops run-
ning buffer.
Fifty micrograms of sample (n = 3/group) was loaded
per well. The gel was run for 1 h at 155 V, and trans-
ferred onto pure nitrocellulose membranes (BioRad).
Antibodies: GAPDH (Millipore, #MAB374), NF-κB (Santa
Cruz, #sc-372), EphA6-R (SantaCruz #25740), MMP-9
(R&D, BAF909), p-mTOR (Cell Signaling, #5536), mTOR
(Cell Signaling, #2983), and ephrinA1 (Santa Cruz, #sc-911)
were followed by appropriate secondary antibodies. All
blots were detected with Immun-Star Horseradish
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CA) and imaged on an Alpha Innotech imaging system
(ProteinSimple, San Jose, CA). Densitometry was performed
using Image J 1.42 software (NIH, Bethesda, MD) and the
intensity of each protein was normalized to GAPDH.
Statistics
ANOVA (analysis of variance) with Student-Newman
Keuls multiple comparison post-hoc analysis illustrated
which groups were statistically different, with significance
of at least p < 0.05.
Results
Survival
The Kaplan-Meier graph in Figure 1 depicts the survival
rates during the first 4 days post-MI. Mice subjected to
STZ +MI had lower cummulative survivals than animals
with only MI. WT (n = 5) and EphA2-R-M (n = 6) con-
trol animals had a cummulative surival of 100% and
83.3% 4 days post-MI, respectively. WT STZ (n = 17)
had a cummulative survival of 70.6% 4 days post-MI and
EphA2-R-M STZ (n = 26) had a cummulative survival of
50% after MI.
Infarct size
Infarct size 4 days post-MI is shown in Figure 2. 4 days
post-MI, the infarct size in WT mouse hearts (n = 12)
was 37.5 ± 4.3% of the left ventricle compared with 49.5 ±Figure 1 Cumulative Survival in WT STZ and EphA2-R-M STZ mice 4 d
is less than that of their WT counterparts (p < 0.05).3.3% in EphA2-R-M mice (n = 10). In hyperglycemic WT
mice, infarct size at 4 days post-MI was 68% ± 7.7% (n = 8)
compared with 51.5 ± 6.2% in EphA2-R-M (n = 9) mice.
There were no differences between LV and chamber
area at 4 days post-MI compared to hyperglycemic mice
of both WT and EphA2-R-M mice at 4 days post-MI.
There were no differences in endocardial myocyte cross-
sectional area (MCSA) among the 8 groups studied. STZ-
treated groups showed a nonsignificant trend to have
decreased epicardial MCSA. Epicardial cardiomyocytes
in EphA2-R-M mice demonstrated a non-significant trend
to hypertrophy post-MI (263.9 ± 15.4 vs 315.0 ± 30.4) but
this was blunted in the STZ-treated EphA2-R-M mice
(203.8 ± 8.9 vs 222.3 ± 21.1). Similarly, there was an in-
crease in the interstitial fibrosis in the remote myocardium
in normoglycymic mice post-MI and this increased nearly
2-fold in hyperglycemic WT mice but did not change in
hyperglycemic EphA2-R-M mice (representative images
Figure 3A-D; numerical Figure 3E).
Ly6-G+ neutrophil density
STZ
Ly6-G+ cell counts to determine neutrophil density in
control and STZ-treated WT and EphA2-R-M mouse
hearts is shown in Figure 4. Neutrophil density in
normoglycemic WT (n = 6) hearts was 0.21 ± 0.04 cells/
0.1 mm2 compared with the normoglycemic EphA2-R-M
(n = 3) hearts with 3.48 ± 0.29 cells/0.1 mm2 (p < 0.01). Inays post-MI. Survival of EphA2-R-M mice post-MI with or without STZ
EFigure 2 Infarct size in WT and EphA2-R-M Normo-and Hyperglycemic mice. Representative images of H&E stains (x20) of normoglycemic
WT mouse heart (A) and EphA2-R-M (B), and hyperglycemic WT (C) and EphA2-R-M (D) mouse hearts. Infarct size (E) in WT mice was 45% larger
in WT hypergylcemic mice compared with normoglycemic mice (p < 0.01). EphA2-R-M mice had slightly with slightly larger infarcts but this was
not exacerbated by hyperglycemia (E).
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density of 4.10 ± 0.91 cells/0.1 mm2 in WT STZ (n = 6)
hearts and 1.24 ± 0.25 cells/0.1 mm2 in EphA2-R-M STZ
(n = 7) hearts (p < 0.05). Neutrophil density in WT STZ
was nearly 19-fold higher than WT controls (p < 0.01).
EphA2-R-M STZ hearts however, had 64% less neutro-
phils than EphA2-R-M controls (p < 0.01).
STZ + MI
Ly6-G+ staining for neutrophil density in the infarct
zone 4 days post-MI (Figure 4) showed an increase inEphA2-R-M (70.04 ± 7.86 cells/0.1 mm2; n = 9) com-
pared with WT (49.38 ± 5.26 cells/0.1 mm2; n = 10)
mouse hearts (p < 0.05). Neutrophil density 4 days post-
MI was not different between the WT + STZ mouse
hearts (92.89 ± 23.34 cells/0.1 mm2) and the EphA2-R-
M + STZ post-MI (91.89 ± 10.25 cells/0.1 mm2). In WT
mice, MI alone increased neutrophil infiltration 103%
over infarcted EphA2-R-M mice (p = 0.06). STZ +MI
only increased neutrophils by a non-significant 31%
in EphA2-R-M compared to STZ +MI WT hearts
(p = 0.12).
EFigure 3 Interstitial Fibrosis. Representative images (x400) of normoglycemic WT mouse heart (A) and EphA2-R-M (B), and hyperglycemic WT
(C) and EphA2-R-M (D) mouse hearts stained with picrosirius red and fast green. Percent interstitial fibrosis (E) was elevated in hyperglycemic WT
mice 4 days post-MI (*, p < 0.05) compared to normoglycemic WT hearts and hyperglycemic EphA2-R-M mouse hearts (¥, p < 0.01).
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STZ
Macrophage density in normoglycemic hearts was no
different between WT (n = 3) and EphA2-R-M (n = 10)
(Figure 5). CD45+ staining of macrophage infiltration in
WT STZ (n = 6) hearts was 18.86 ± 1.22 cells/0.1 mm2
compared with the EphA2-R-M STZ (n = 6) with 15.85 ±
0.91 cells/0.1 mm2 (p = 0.07). There was a 147% increase
in macrophage infiltration in WT STZ (n = 6) compared
with WT controls (n = 3) (p < 0.01). In EphA2-R-M STZ
(n = 6), there was an insignificant increase of only 26%
in macrophage infiltration compared with EphA2-R-M
controls (p = 0.22).
STZ + MI
Macrophage density 4 days post-MI (Figure 5) in normo-
glycemic WT (n = 7) hearts was 55.97 ± 5.94 cells/
0.1 mm2 compared with the normoglycemic EphA2-R-M(n = 8) hearts with 102.76 ± 5.94 cells/0.1 mm2 (p < 0.001).
Macrophage density was no different after MI in WT STZ
(n = 5) and EphA2-R-M STZ (n = 5) hearts (p = 0.65).
Macrophage infiltration was 17% less in WT STZ (n = 5)
hearts after MI compared with WT (n = 7) hearts (p =
0.34). However, EphA2-R-M STZ hearts post-MI (n = 5)
had 64% less macrophages than EphA2-R-M hearts after
MI (n = 8) (p < 0.01).
Serum cytokines
Serum cytokine levels are shown in Figure 6. Of the 40
cytokines tested by the array, only 10 were expressed in
the samples tested and 4 of these, TREM, TNF-α, IL-1α,
and MIG were only detected in the EphA2-R-M 4d +
STZ group (data not shown).
C5a and sICAM-1 were present in all groups (panels
A - D) whereas M-CSF, MCP-1, KC, and TIMP-1 were
only detected in injured hearts (panels E- H).
*¥*
¥
¥
Figure 4 Neutrophil Infiltration in WT STZ and EphA2-R-M STZ hearts. Neutrophil density in the infarct zone before (top) and after (bottom)
MI. *Different from control, p < 0.001; ¥ Different from WT, p < 0.001.
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STZ
Endocardial capillary density in WT control (n = 6)
hearts was 167 ± 18 vessels per 400x high power field
and 121 ± 8 vessels per 400x high power field in EphA2-
R-M control (n = 5) hearts (p < 0.05). In WT STZ hearts
(n = 5), endocardial capillary density was reduced by 82%
compared with control hearts (p < 0.001). EphA2-R-M
STZ hearts (n = 5) observed a decrease in capillary dens-
ity in the endocardium by 89% compared with WT con-
trol hearts (p < 0.001). EphA2-R-M STZ (n = 5) hearts
had 54% less capillaries in the endocardium than WT
STZ (n = 5) hearts (p < 0.01). These results are shown in
Figure 7A.
STZ + MI
Endocardial CD31+ staining 4 days post-MI showed that
capillary density was reduced by 63% in normoglycmic
EphA2-R-M (n = 6) hearts compared with WT (n = 4)
(p < 0.05). After MI, WT STZ (n = 5) had an increase in
capillary density of 109% compared with WT control(n = 4) hearts. (p < 0.05). EphA2-R-M STZ (n = 4) had
53% less capillaries than EphA2-R-M control (n = 6)
hearts after MI (p < 0.05). EphA2-R-M STZ (n = 4) had
92% less capillary density than WT STZ (n = 5) after
infarction (p < 0.01). These results are depicted in
Figure 7A.
Epicardial capillary density in WT control (n = 6) hearts
was 108.97 ± 12.98 vessels per 400x high power field and
100.90 ± 11.71 vessels per 400x high power field in EphA2
control (n = 5) hearts (p = 0.65). In WT STZ hearts (n = 5),
epicardial capillary density was reduced by 80.3% com-
pared with WT control hearts (p < 0.001). EphA2 STZ
hearts (n = 5) observed a decrease in capillary density in
the epicardium by 86% compared with EphA2-R-M
control hearts (p < 0.001). EphA2 STZ (n = 5) hearts had
33.3% less capillaries in the epicardium than WT STZ
(n = 5) hearts (p = 0.15). These results are shown in
Figure 7B.
Epicardium CD31+ staining 4 days post-MI was 27.38 ±
1.99 vessels per 400x high power field in WT control
(n = 4) hearts and 9.04 ± 0.73 vessels per 400× high
Figure 5 Macrophage Infiltration in WT STZ and EphA2-R-M STZ hearts. Macrophage density in the infarct zone of control hearts (top; *Different
from control, p < 0.001; ¥ Different from WT, p < 0.001) and post-MI (bottom; *Different from MI, p < 0.001; ¥ Different from WT, p < 0.001).
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(p < 0.01). WT STZ (n = 5) had an increase in epicardial
capillary density of 46% compared with WT (n = 4) hearts
after infarction (p < 0.01). EphA2 STZ (n = 4) had a 26.4%
decrease in epicardial capillary density compared with
EphA2 (n = 6) control hearts after MI (p = 0.25). After
infarction, EphA2 STZ (n = 4) hearts had 83.4% less epi-
cardial capillaries than WT STZ (n = 5) hearts (p < 0.001).
These results are depicted in Figure 7B.Echocardiography
STZ
Echocardiographic parameters for each of the 8 groups
are presented in Table 1. Although there was no differ-
ence in EF between WT and EphA2-R-M mice, FS was
depressed in EphA2-R-M mice and this difference was
also present in hyperglycemic mice. Hyperglycemic
EphA2-R-M mice also had reduced HR while WT mice
had increased SBP and DBP. There were no differences
in LV mass between uninjured normoglycemic and hyper-
glycemic EphA2-R-M and WT mice.STZ + MI
EF and FS in both WT and EphA2-R-M mice 4 days
post-MI were not different from their respective uninjured
controls but diastolic diameter and volume as well as
systolic volume are elevated in WT mice 4 days post-MI
compared with uninjured control. Hyperglycemic WT
and EphA2-R-M mice had depressed cardiac function
4 days post-MI compared with respective normoglycemic
infarcted mice. Systolic diameter and volume were only el-
evated in WT mice There was no difference in LV mass in
infarcted STZ mice but the EphA2-R-M mice did not
exhibit proportionate compensatory hypertrophy dem-
onstrated by the WT mice 4 days post-MI.qRT-PCR
STZ
EphrinA1 and EphA-R receptor gene expression was
quantified using qRT-PCR mRNA levels for WT STZ
mice (n = 4) and EphA2-R-M STZ mice (n = 5) (Figure 8).
EphrinA1 ligand expression exhibited a non-significant
trend to increase (1.24-fold; p = 0.08) in EphA2-R-M
Figure 6 (See legend on next page.)
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Figure 6 Serum Cytokines in Normoglycemic and Hyperglycemic WT and EphA2-R-M mice. Panel A and C show the differences in C5a
and sICAM-1 between normoglycemic and hyperglycemic WT and EphA2-R-M mice. Panel B and D shows how C5a and sICAM-1 change post-MI.
Panels E-H show post-MI changes in WT versus EphA2-R-M mice in serum levels of KC, MCP-1, M-CSF, and TIMP-1. (p < 0.05: *different from WT,
●different from WT STZ, ‡different from WT 4d, ¥different from EphA2-R-M 4d, †different from WT 4d STZ).
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exhibited a non-significant trend to increase (2.01-fold,
p = 0.06) in EphA2-R-M STZ hearts compared with WT
STZ hearts.STZ + MI
EphrinA1 and Eph Receptor gene expression was also
quantified for WT STZ (5) and EphA2-R-M STZ (4)
after infarction (Figure 8). Similar to uninjured STZ
hearts, ephrinA1 and EphA6 were higher among
EphA2-R-M STZ hearts after infarction. EphrinA1
was increased 1.19-fold (p < 0.05) and EphA6 was in-
creased nearly 4.5-fold (p < 0.05) in EphA2-R-M STZ
hearts after infarction.Figure 7 Endocardial (A) and Epicardial (B) Capillary Density in WT an
the endocardium of uninjured control hearts from normoglycemic (left) an
p < 0.001; ¥ Different from WT, p < 0.01) and hearts 4 days post-MI (bottom
top graph shows the capillary density in the epicardium of uninjured contr
hearts (*Different from control, p < 0.001) and hearts 4 days post-MI (bottoWestern blotting
STZ
Representative blots for ephrinA1 and EphA6-R in WT
mice (left) and EphA2-R-M mice (right) are shown in
Figure 9. There were no statistically significant differ-
ences in expression of NF-κB, MMP-9, or p-mTOR/
mTOR in response to STZ in either group (data not
shown).STZ + MI
Although not significant, there was a trend for reduced
ephrinA1 (13%) expression in normoglycemic WT
hearts post-MI and increased EphA6-R expression in
both normoglycemic and hyperglycemic WT and EphA2-d EphA2-R-M hearts. A: The top graph shows the capillary density in
d hyperglycemic (right; STZ) hearts (top; *Different from control,
; *Different from MI, p < 0.001; ¥ Different from WT, p < 0.01). B: The
ol hearts from normoglycemic (left) and hyperglycemic (right; STZ)
m; *Different from MI, p < 0.01; ¥ Different from WT, p < 0.001).
Table 1 Cardiac function and blood pressure parameters
Parameter EF FS LVIDd LVIDs LV vold LV vols HR SBP DBP LV mass
WT (n=6) 91 ± 3 60 ± 4 2.7 ± 0.3 1.1 ± 0.1 27.8 ± 7.2 2.5 ± 0.5 619 ± 98 132 ± 4 81 ± 3 102 ± 22
EphA2-R-M (n=9) 82 ± 4 49 ± 4* 2.7 ± 0.2 1.4 ± 0.2 27 ± 5.7 4.8 ± 1.5 636 ± 71 129 ± 4 77 ± 2 71 ± 15
WT STZ (n=8) 88 ± 2 57 ± 3 2.8 ± 0.2 1.2 ± 0.1 30.1 ± 4.7 3.6 ± 0.9 578 ± 98 185 ± 6* 107 ± 11* 69 ± 11
EphA2-R-M STZ (n=18) 78 ± 6 46 ± 6● 2.7 ± 0.2 1.5 ± 0.2 27.8 ± 5.6 6.1 ± 2.4 492 ± 142† 148 ± 4 91 ± 3 60 ± 15
WT 4d (n=7) 77 ± 1 45 ± 5 3.4 ± 0.4* 1.9 ± 0.3 51.0 ± 14.1* 13.5 ± 5.4* 658 ± 91 129 ± 8 73 ± 5 169 ± 51
EphA2-R-M 4d (n-8) 79 ± 3 46 ± 3 3.2 ± 0.1 1.7 ± 0.1 39.5 ± 2.2 8.5 ± 1.5 632 ± 93 126 ± 4 76 ± 3 94 ± 24‡
WT STZ + 4d (n=7) 55 ± 13‡ 28 ± 8‡ 3.3 ± 0.3 2.4 ± 0.5‡ 44.9 ± 10.0 21.0 ± 9.1‡ 602 ± 98 127 ± 6 73 ± 7 107 ± 32‡
EphA2-R-M STZ + 4d (n=11) 62 ± 12¥ 33 ± 8¥ 3.1 ± 0.7 2.1 ± 0.5 39.7 ± 18.6 15.4 ± 9.2 536 ± 80 130 ± 5 69 ± 2 81 ± 40
Echocardiography and blood pressure measures from conscious WT, EphA2-R-M, WT STZ, EphA2-R-M STZ, WT 4d, EphA2 3d, WT STZ + 4d, and EphA2-R-M STZ + 4d mice
(p<0.05: *different from WT, †different from EphA2-R-M, ●different from WT STZ, ‡ different from WT 4d, ¥different from EphA2-R-M 4d).
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http://www.cardiab.com/content/13/1/114R-M hearts (11%) post-MI. There were no significant
differences in NF-κB, MMP-9, or p-mTOR/mTOR
expression between the two groups (data not shown).
Discussion
Cardiomyocyte death post-MI starts immediately after
coronary occlusion and occurs downstream from the¥
A
B
Figure 8 Gene Expression of EphrinA1 and Eph Receptors in WT and
significant differences between any of the genes tested in uninjured contro
post-MI. ¥ Different from WT (p < 0.05).occlusion. The therapeutic goal to decrease infarct size
to less than 20% of the left ventricle has shown to
improve long-term prognosis [23]. Early diagnosis and
treatment are critical but presently inadequate. Admi-
nistering a recombinant protein alone or in conjunction
with grafting cells has reduced early injury as well as
adverse remodeling and subsequent cardiac dysfunction¥
EphA2-R-M STZ hearts before (A) and after (B) MI. There were no
l hearts but ephrinA1and EphA6-R were elevated in EphA2-R-M hearts
Figure 9 Western blots. Representative samples of left ventricles of uninjured and infarcted hearts from normoglycemic and hyperglycemic WT
(left) and EphA2-R-M (right) mice probed with ephrinA1 (top) and EphA6-R (bottom) and normalized to GAPDH.
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plasty or thrombolysis has been proven to reduce early
injury. Although late remodeling cannot be significantly
altered, it is managed with pharmacologic agents which
sustain ventricular function but this merely delays the
progression to heart failure. Current therapeutics, such
as early myocardial revascularization after myocardial
infarction, are geared toward minimizing cardiac myo-
cyte necrosis and may modulate apoptosis and autoph-
agy [30]. Research that explores the number and type of
cells for grafting alone or in combination with gene
and protein-based therapeutic strategies are aimed at
augmenting the cardiac regenerative potential and pro-
moting tissue salvage. Due to poor reproducibility and
efficacy, as well as untoward side effects, none of these
experimental paradigms have been successfully trans-
lated into clinical therapies. Due to these factors and
the narrow window of opportunity between the initial
cardiac insult and the cellular demise, developing newer
therapies for “cellular resuscitation” are of paramount
importance [31–33].
Diabetes has long been associated with greater incidence
of myocardial infarction, inadequate healing, and suscepti-
bility to further events. Hyperglycemia, the principal mani-
festation of all types of diabetes, results in perturbations in
cellular metabolism, oxidative stress, exacerbated inflam-
mation, and AGE-modified proteins that culminate in tis-
sue damage, cardiac dysfunction, and impaired wound
healing responses [34–42]. Sweeney et al. (2012) observed
decreased glucose uptake and increased autophagy after
acute I/R injury in STZ hearts, however, long term studies
reveal detrimental effects on remodeling that ultimately
compromise performance [43].
The EphA2-R has historically been known to regulate
apoptosis in developing vasculature and nervous systemand cell death during tumorigenesis [5,44–50], the
EphA2-R also modulates vascular permeability, inflamma-
tion, and ischemic injury [11,12,14,51–59]. Knockdown of
EphA2-R in HUVECs suppresses thrombin-induced phos-
phorylation of NF-κB, resulting in decreased ICAM-1 ex-
pression [59]. We observed increased sICAM-1 in serum
of WT mice post-MI but this is blunted in hyperglycemic
mice. Interestingly, sICAM-1 is decreased in hypergly-
cemic EphA2-R-M mice compared to normoglycemic
mice and is not detected post-MI but is increased in
hyperglycemic EphA2-R-M post-MI. EphrinA1 and EphA2
are both upregulated in response to inflammation [60–62].
Although we did not detect differences in NF-kB expres-
sion, we did observe decreased ephrinA1 expression in
EphA2-R-M mice post-MI, and propose that the deficiency
of EphA2-R prevents timely induction of inflammatory
cascades necessary for mediating repair. Further, cardiac
ephrinA1 expression exhibited an non-significant trend
to increase slightly in hyperglycemic WT mice post-MI
but not to the extent that they are expressed in unin-
jured normoglycemic mice, and is thus likely ineffective
in eliciting the protective effects known to occur from
exogenous administration of ephrinA1-Fc [13–15]. TNF-
α, IL-1α, MIG, and TREM were only detectable in serum
of hyperglycemic EphA2-R-M mice, and significant eleva-
tion of MCP-1, TIMP-1, and C5a, which typically correlate
with the severity of injury, suggests exacerbated wound
healing in EphA2-R-M mice [63–67]. Additionally, KC
and M-CSF are reduced in hyperglycemic EphA2-R-M
mice post-MI, implying poor monocyte adhesion and dif-
ferentiation [63,68–70]. This is supported by the reduced
leukocyte infiltration observed in this group, and although
cardiac function is not worsened, the increased mortality
in this group indicates that inadequate healing mecha-
nisms acutely result in lethality. Indeed, plasma sICAM-1
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been shown to correlate with increased risk of cardiovas-
cular events [71,72], providing further support for the con-
tinuity of our findings.
We have previously shown that intramyocardial ad-
ministration of ephrinA1-Fc reduces early injury in
non-reperfused myocardium via reduced inflammatory
cell infiltration and changes in gene expression of several
EphA-Rs. The mechanisms by which this protection oc-
curs can be multifaceted depending on the EphA recep-
tors activated/inhibited and the expression profile of the
various cells involved. Goichberg et al. (2012) showed
ephrinA1-Fc enhanced motility of EphA2-expressing
hCSCs, promoting infarct repair [14]. In adult mouse
immortalized HL-1 cardiomyocytes, increased EphA2
expression and reduced phosphorylation following litho-
cholic acid treatment prevented doxazosin-induced apop-
tosis via inhibition of SHP-2 [73]. Clearly, the EphA2
receptor plays a vital role in myocardial tissue viability and
more studies to understand the signaling pathways in-
volved are warranted.
Expression of the EphA6 receptor gene decreases in
response to injury and stays decreased with ephrinA1-Fc
[13]. Previous work has shown it to be expressed in
genital tubercle vascular endothelia and expression is
regulated by HOXA13, a homeobox gene [74]. HOXA13
is also a transcriptional regulator of appropriate vessel
morphology and function of the developing placenta
[75]. In a recent study, we showed that the EphA6-R
localizes to the vasculature and increased in response to
injury in EphA2-R-M mouse hearts [76], suggesting that
EphA6-R compensates for the absence of EphA2-R. In
the current study, only EphA6 was different between unin-
jured normoglycemic and hyperglycemic WT and EphA2-
R-M mouse hearts. While not altered significantly by
hyperglycemia at 4 days post-MI in either strain, it was el-
evated post-MI in all groups. EphA6 is expressed in adult
human monocytes and coronary artery endothelial cells
[77]. Therefore, given that several ephrins and Eph recep-
tors are upregulated during injury in various cell types,
they may play a role in chemotaxis and extravasation and
provide insights into the mechanisms of inflammatory dis-
eases and damage resolution [78–80].
Conclusions
This research ratifies our understanding of the negative
impact of hyperglycemia on the form and function of
the wild type heart. Hyperglycemia leads to decreased
survival following MI, impaired compensatory hyper-
trophy of cardiomyocytes, and increased interstitial fibro-
sis of the left ventricle. Superimposing hyperglycemia on
the infarcted transgenic EphA2-R-M mouse impaired the
response to injury and significantly increased mortality.
These studies provide the baseline data needed to beginunraveling the role of EphA2-R in modulating inflamma-
tion and evaluate the potential impact of ephrinA1-Fc use
in the treatment of MI in the hyperglycemic myocardium.
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